Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-01
2000-09-19
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 81, 5142228, 5142245, 5142262, 5142292, 5142298, 514243, 514248, 514267, 514291, 514293, 544 32, 544 66, 544 95, 544183, 544234, 544250, 546 21, 546 81, 546 82, 546 83, 546 84, A61K 314375, C07D47106
Patent
active
061212784
ABSTRACT:
A compound of formula I: ##STR1## or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, heterocyclic ring containing at least one nitrogen heteroatom in a 1,3-relationship with the nitrogen atom depicted in formula I, wherein Y may be unsubstituted or substituted with at least one alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, or --COOR.sup.5 group, or a moiety selected from the group consisting of: ##STR2## wherein R.sup.5 and R.sup.7 are independently hydrogen or alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, or aryl.
REFERENCES:
patent: Re31617 (1984-06-01), Beverung, Jr. et al.
patent: 1895105 (1933-01-01), Rath et al.
patent: 2467692 (1949-04-01), Petrow
patent: 3300499 (1967-01-01), Lesher
patent: 3557119 (1971-01-01), Humber
patent: 3573304 (1971-03-01), Eberle et al.
patent: 3700673 (1972-10-01), Watson
patent: 3900477 (1975-08-01), Philipp et al.
patent: 3950343 (1976-04-01), Philipp et al.
patent: 3978066 (1976-08-01), Philipp et al.
patent: 3991064 (1976-11-01), Brown et al.
patent: 4031097 (1977-06-01), Bach et al.
patent: 4472401 (1984-09-01), Kennewell et al.
patent: 4742171 (1988-05-01), Martin et al.
patent: 4902695 (1990-02-01), Ornstein
patent: 5041653 (1991-08-01), Lee et al.
patent: 5338851 (1994-08-01), Huff et al.
patent: 5414001 (1995-05-01), Ireland et al.
patent: 5420136 (1995-05-01), Lewis et al.
patent: 5589483 (1996-12-01), West
patent: 5618813 (1997-04-01), Chu et al.
patent: 5756510 (1998-05-01), Griffin et al.
patent: 5767135 (1998-06-01), Fernandez-Pol
Molina et al., Chemical Abstracts, vol. 116, abstract 255509, 1992.
Marek Banasik et al, "Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase", Journal of Biological Chemistry, vol. 267, 1569-75 (1992).
Roger J. Griffin et al., "Novel Potent Inhibitors of the DNA Repair Enzyme Poly (ADP-Ribose) Polymerase (PARP)", Anti-Cancer Drug Design, vol. 10, No. 6, pp. 507-14 (1995).
M.J. Suto et al., "Dihydroisoquinolinones: the Design and Synthesis of a New Series of Potent Inhibitors of Poly (ADP-Ribose) Polymerase", Anti-Cancer Drug Design, vol. 7, pp. 107-17 (1991).
Bauer et al., "Modification of Growth Related Enzymatic Pathways and Apparent Loss of Tumorigenicity of a ras-transformed Bovine Endothelial Cell Line by Treatment with 5-Iodo-6-amino-1,2-benzopyrone (INH.sub.2 BP)", Intl. J. Oncol., 8:239-52, (1996).
Cosi et al., "Poly (ADP-Ribose) Polymerase (PARP) Revisited. A New Role for an Old Enzyme: PARP Involvement in Neurodegeneration and PARP Inhibitors as Possible Neuroprotective Agents", Ann. N. Y. Acad. Sci., 825:366-79 (1997).
Cosi et al., "Poly (ADP-Ribose) Polymerase Inhibitors Protect Against MPTP-induced Depletions of Striatal Dopamine and Cortical Noradrenaline in C57B1/6 Mice", Brain Res., 729:264-69, (1996).
Cristovao et al., "Effect of a Poly (ADP-Ribose) Polymerase Inhibitor on DNA Breakage and Cytotoxicity Induced by Hydrogen Peroxide and .gamma.-Radiation", Terato., Carcino., and Muta., 16:219-27, (1996).
Cuzzocrea, "Role of Peroxynitrite and Activation of Poly (ADP-Ribose) Synthetase in the Vascular Failure Induced by Zymosan-activated Plasma"m Brit. J. Pharm., 122:493-503, (1997).
Endres et al., "Ischemic Brain Injury is Mediated by the Activation of Poly (ADP-Ribose) Polymerase," J. Cerebral Flood Flow Metabol., 17 (11):1143-51 (1997).
Heller et al., "Inactivation of the Poly (ADP-Ribose) Polymerase Gene Affects Oxygen Radical and Nitric Oxide Toxicity in Islet Cells", J. Biol. Chem., 270:11176-80 (1995).
Hughes et al., "Induction of T Helper Cell Hyporesponsiveness in an Experimental Model of Autoimmunity by Using Nonmitogenic Anti-CD3 Monoclonal Antibody", J. Immuno., 153:3319-25 (1994).
Salzman et al., "Role of Peroxynitrite and Poly (ADP-Ribose) Synthase Activation Experimental Colitis", Japanese J. Pharm., 75, Supp. I:15 (1997).
Southan et al., "Spontaneous Rearrangement of Aminoalkylisothioureas into Mercaptoalkylguanidines, a Novel Class of Nitric Oxide Synthase Inhibitors with Selectivity Towards the Inducible Isoform", Br. J. Pharm., 117:619-32 (1996).
Szabo et al., "DNA Strand Breakage, Activation of Poly (ADP-Ribose) Synthetase, and Cellular Energy Depletion are Involved in the Cytotoxicity in Macrophages and Smooth Muscle Cells Exposed to Peroxynitrite", Proc. Natl. Acad. Sci. USA, 93:1753-58 (1996).
Szabo et al., "Mercaptoethylguanidine and Guanidine Inhibitors of Nitric Oxide Synthase React with Peroxynitrite and Protect Against Peroxynitrite-induced Oxidative Damage", J. Biol. Chem., 272:9030-36 (1997).
Szabo et al., "Protective Effects of an Inhibitor of Poly (ADP-Ribose) Synthetase in Collagen-Induced Arthritis," Japanese J. Pharm., 75, Supp. I:102 (1997).
Wallis et al., Traumatic Neuroprotection with Inhibitors of Nitric Oxide and ADP-Ribosylation, Brain Res., 710:169-77 (1996).
Weltin et al., "Effect of 6 (5.sub.H)-Phenanthridinone, an Inhibitor of Poly (ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncol. Res., 6:399-403 (1994).
Zingarelli et al., "Protective Effects of Nicotinamide Against Nitric Oxide-Mediated Delayed Vascular Failure in Endotoxic Shock: Potential Involvement of PolyADP Ribosyl Synthetase", Shock, 5:258-64 (1996).
Desilets et al., "Design and Synthesis of Near-Infrared Absorbing Pigments", Can. J. Chem., 73, 319-35 (1995). (Part I and Part II).
Langlois et al., "Synthesis of Quinazoline-2, 4-dione and Naphthalimide Derivatives as New 5-HT3 Receptor Antagonists", Eur. J. Med. Chem., 29, 925-40 (1994).
Mao et al., "The inhibition of nitric oxide-activated poly (ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat", Pain vol. 72, pp. 355-366 (1997).
Purnell et al., "Novel Inhibitors of Poly (ADP-Ribose) Synthase", Biochem. J., 185, 775-77 (1980).
Ruf et al., "Structure of the catalytic fragment of poly (ADP-ribose) polymerase from chicken", Proc. Natl. Acad. Sci. USA vol. 93, pp. 7481-7485 (Jul. 1996).
Vaziri et al., "ATM-dependent telomere loss in aging human dipoloid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly (ADP-ribose) polymerase", The EMBO Journal vol. 16 No. 19, pp. 6018-6033 (1997).
Jackson Paul F.
Maclin Keith M.
Zhang Jie
Guilford Pharmaceuticals Inc.
Raymond Richard L.
LandOfFree
Di-n-heterocyclic compounds, methods, and compositions for inhib does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Di-n-heterocyclic compounds, methods, and compositions for inhib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Di-n-heterocyclic compounds, methods, and compositions for inhib will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073534